AcelRx Pharmaceuticals Inc (ACRX.O)
9.85USD
1 Jul 2013
$0.58 (+6.26%)
$9.27
$9.31
$9.93
$9.15
422,906
478,537
$10.59
$2.27
ACRX.O
About
Overall
| Beta: | -- |
| Market Cap (Mil.): | $366.79 |
| Shares Outstanding (Mil.): | 37.24 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ACRX.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 34.05 | 33.02 |
| EPS (TTM): | -1.48 | -- | -- |
| ROI: | -123.92 | -2.50 | 19.07 |
| ROE: | -237.06 | -3.10 | 20.00 |
AcelRX post-op pain treatment meets late-stage study goal
- AcelRX Pharmaceuticals Inc said its experimental treatment for post-operative pain met its main goal in a late-stage trial of patients who had undergone knee or hip replacement surgery, sending its shares up 15 percent.
UPDATE 1-Higher dose of AcelRx pain drug meets trial goal
* AcelRx says 20 mcg dose not better than placebo in mid-stage trial
AcelRx pain drug shows mixed results in mid-stage trial
April 24 - AcelRx Pharmaceuticals Inc said a mid-stage trial of its experimental pain drug showed that a higher dose of the therapy met the main goal of reducing acute pain in patients, but the lower dose failed to meet the goal.
AcelRx post-operative pain treatment meets late-stage study goal
- AcelRx Pharmaceuticals Inc said its experimental drug-device combination to manage post-operative pain met the main goal of a late-stage study on patients who have undergone major open abdominal surgery.
AcelRx pain treatment meets late-stage study goal
- AcelRx Pharmaceuticals Inc said its experimental drug-device combination for post-operative pain met the main goal of a late-stage study on patients who have undergone major open abdominal surgery.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Streetwise Reports
|
$58.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
